Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.5 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.73 | |||||
Beneish M-Score | 1.98 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.6 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -57.7 | |||||
3-Year Book Growth Rate | 34.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 302.13 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.49 | |||||
9-Day RSI | 46.62 | |||||
14-Day RSI | 45.23 | |||||
6-1 Month Momentum % | -38.71 | |||||
12-1 Month Momentum % | -17.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.68 | |||||
Quick Ratio | 6.68 | |||||
Cash Ratio | 5.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -1.49 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -28353.97 | |||||
Net Margin % | -15363.23 | |||||
FCF Margin % | -20757.79 | |||||
ROE % | -26.11 | |||||
ROA % | -21.67 | |||||
ROIC % | -112.8 | |||||
3-Year ROIIC % | -34.78 | |||||
ROC (Joel Greenblatt) % | -2499.31 | |||||
ROCE % | -21.79 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 625 | |||||
PB Ratio | 1.25 | |||||
Price-to-Tangible-Book | 1.25 | |||||
EV-to-EBIT | -2.53 | |||||
EV-to-Forward-EBIT | -0.86 | |||||
EV-to-EBITDA | -2.55 | |||||
EV-to-Forward-EBITDA | -1.08 | |||||
EV-to-Revenue | 364.54 | |||||
EV-to-Forward-Revenue | 183.16 | |||||
EV-to-FCF | -1.78 | |||||
Price-to-Net-Current-Asset-Value | 2.95 | |||||
Price-to-Net-Cash | 5.1 | |||||
Earnings Yield (Greenblatt) % | -39.52 | |||||
FCF Yield % | -38.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.353 | ||
EPS (TTM) (€) | -0.357 | ||
Beta | 0.76 | ||
Volatility % | 61.54 | ||
14-Day RSI | 45.23 | ||
14-Day ATR (€) | 0.038418 | ||
20-Day SMA (€) | 1.143925 | ||
12-1 Month Momentum % | -17.98 | ||
52-Week Range (€) | 0.9434 - 2.475 | ||
Shares Outstanding (Mil) | 167.8 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ATAI Life Sciences NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(FRA:9VC)'s stock price today?
When is next earnings date of ATAI Life Sciences NV(FRA:9VC)?
Does ATAI Life Sciences NV(FRA:9VC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |